Phase I Study of Pomalidomide, Dexamethasone and Rituximab (PDR) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Trial Profile

Phase I Study of Pomalidomide, Dexamethasone and Rituximab (PDR) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 14 Aug 2015 Planned End Date changed from 1 May 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 14 Aug 2015 Planned primary completion date changed from 1 May 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top